⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025Open Access

Supplementary Figure S2 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer

Tony Georgiev Sara Puglioli Lucrezia Principi Ettore Gilardoni Christian Pellegrino Gabriele Bassi Andrea Galbiati Dario Neri Samuele Cazzamalli

View Full Paper

Ask AI

Bookmark

Share

Key Points

Improved targeting of prostate cancer was demonstrated using small molecule–drug conjugates.
The presence of a peptidase-cleavable linker enhances the effectiveness of the drug delivery.
The study utilized chromatograms to analyze the compounds, confirming their potential as targeted therapies.
These findings support further development of targeted treatments for prostate cancer using novel drug conjugates.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Research presents PSMA-targeted small molecule drug conjugates, suggesting improved targeting for prostate cancer therapies.

Abstract

LC chromatogram of I2

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Georgiev et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21a54 https://doi.org/10.1158/1535-7163.30255233

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
2Supplementary Figure S3 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
3Supplementary Figure S5 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
4Supplementary Figure S4 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
5Supplementary Figure S6 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025

More related papers

Supplementary Figure S8 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
Supplementary FIgure S7 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
Supplementary Figure S10 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025